S&P 500   4,284.62 (-0.08%)
DOW   33,417.07 (-0.27%)
QQQ   359.25 (+0.27%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
S&P 500   4,284.62 (-0.08%)
DOW   33,417.07 (-0.27%)
QQQ   359.25 (+0.27%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
S&P 500   4,284.62 (-0.08%)
DOW   33,417.07 (-0.27%)
QQQ   359.25 (+0.27%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
S&P 500   4,284.62 (-0.08%)
DOW   33,417.07 (-0.27%)
QQQ   359.25 (+0.27%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
NASDAQ:SRDX

Surmodics (SRDX) Stock Forecast, Price & News

$31.70
-0.39 (-1.22%)
(As of 09:35 AM ET)
Compare
Today's Range
$30.99
▼
$31.74
50-Day Range
$31.10
▼
$38.36
52-Week Range
$16.00
▼
$39.41
Volume
3,972 shs
Average Volume
117,315 shs
Market Capitalization
$447.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Surmodics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.7% Upside
$59.50 Price Target
Short Interest
Healthy
0.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.52
Upright™ Environmental Score
News Sentiment
1.28mentions of Surmodics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.22) to ($0.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

479th out of 969 stocks

Surgical & Medical Instruments Industry

57th out of 100 stocks

See Top Rated MarketRank™ Stocks Here

SRDX stock logo

About Surmodics (NASDAQ:SRDX) Stock

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

SRDX Price History

SRDX Stock News Headlines

September 26, 2023 | americanbankingnews.com
Surmodics (NASDAQ:SRDX) Share Price Crosses Above 200 Day Moving Average of $27.22
September 12, 2023 | finance.yahoo.com
Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?
October 2, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 6, 2023 | finance.yahoo.com
Why You Should Add Surmodics (SRDX) Stock to Your Portfolio
August 9, 2023 | finance.yahoo.com
Surmodics to Participate in Upcoming Investor Conferences in August
August 3, 2023 | finance.yahoo.com
Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up
August 3, 2023 | msn.com
Needham Reiterates Surmodics (SRDX) Buy Recommendation
August 2, 2023 | finance.yahoo.com
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
August 2, 2023 | finance.yahoo.com
SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates
August 2, 2023 | finance.yahoo.com
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
July 12, 2023 | finance.yahoo.com
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
June 28, 2023 | finance.yahoo.com
Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
June 22, 2023 | msn.com
Surmodics: Regulatory, Fundamental Catalysts Show 90% Upside Potential
June 21, 2023 | bizjournals.com
Surmodics stock jumps on FDA approval of SurVeil drug-coated balloon
June 21, 2023 | finance.yahoo.com
Strength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?
June 20, 2023 | msn.com
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
June 20, 2023 | startribune.com
Eden Prairie's Surmodics receives key FDA approval, unlocking a $27M milestone payment
June 20, 2023 | finance.yahoo.com
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval
June 20, 2023 | finance.yahoo.com
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
June 16, 2023 | finance.yahoo.com
Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care
June 14, 2023 | finance.yahoo.com
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
June 13, 2023 | markets.businessinsider.com
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application
June 13, 2023 | msn.com
Needham Upgrades Surmodics (SRDX)
June 4, 2023 | fool.com
Surmodics (NASDAQ: SRDX)
May 25, 2023 | finance.yahoo.com
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
May 16, 2023 | finance.yahoo.com
Here's Why SurModics (SRDX) Is a Great 'Buy the Bottom' Stock Now
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Company Calendar

Last Earnings
8/02/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
9/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:SRDX
CUSIP
86887310
CIK
924717
Web
www.surmodics.com
Phone
(952) 500-7000
Fax
952-500-7001
Employees
447
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$59.50
High Stock Price Forecast
$69.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+87.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,270,000.00
Net Margins
-17.58%
Pretax Margin
-1.16%
Return on Equity
-8.34%
Return on Assets
-5.26%

Debt

Debt-to-Equity Ratio
0.26
Current Ratio
2.68
Quick Ratio
2.22

Sales & Book Value

Annual Sales
$99.95 million
Price / Sales
4.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.75 per share
Price / Book
4.09

Miscellaneous

Outstanding Shares
14,130,000
Free Float
13,074,000
Market Cap
$447.92 million
Optionable
Optionable
Beta
1.16

Social Links

10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Gary R. MaharajMr. Gary R. Maharaj (Age 60)
    CEO, Pres & Director
    Comp: $1.1M
  • Mr. Timothy J. Arens (Age 56)
    Sr. VP of Fin. & Information Technology and CFO
    Comp: $545.83k
  • Mr. Gordon S. Weber (Age 60)
    Sr. VP of Legal, Gen. Counsel & Sec.
    Comp: $519.6k
  • Mr. Charles W. OlsonMr. Charles W. Olson (Age 59)
    Sr. VP & Pres of Medical Device Coatings
    Comp: $523.12k
  • Ms. Teryl L. W. Sides (Age 53)
    Sr. VP & Pres of Vascular Interventions
    Comp: $613.02k
  • Mr. John D. Manders (Age 42)
    Corp. Controller, VP of Fin. & Principal Accounting Officer
  • Mr. Joseph J. StichMr. Joseph J. Stich (Age 58)
    Sr. VP of HR & Pres of In Vitro Diagnostics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SRDX Stock - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings or view top-rated stocks.

What is Surmodics' stock price forecast for 2023?

2 equities research analysts have issued 12 month target prices for Surmodics' shares. Their SRDX share price forecasts range from $50.00 to $69.00. On average, they expect the company's stock price to reach $59.50 in the next year. This suggests a possible upside of 87.7% from the stock's current price.
View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2023?

Surmodics' stock was trading at $34.12 on January 1st, 2023. Since then, SRDX shares have decreased by 7.1% and is now trading at $31.70.
View the best growth stocks for 2023 here.

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SRDX earnings forecast.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) announced its earnings results on Wednesday, August, 2nd. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.98. The company had revenue of $52.48 million for the quarter, compared to analyst estimates of $26.70 million. Surmodics had a negative trailing twelve-month return on equity of 8.34% and a negative net margin of 17.58%.

What ETF holds Surmodics' stock ?

Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics issued an update on its FY 2023 earnings guidance on Saturday, August, 5th. The company provided EPS guidance of -$0.29--$0.14 for the period, compared to the consensus EPS estimate of -$1.30. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $116.95 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $31.70.

How much money does Surmodics make?

Surmodics (NASDAQ:SRDX) has a market capitalization of $447.92 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Surmodics have?

The company employs 447 workers across the globe.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.

This page (NASDAQ:SRDX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -